Renal denervation is a moderately novel therapy to cure uncontrolled hypertension. It is a simple omnipresent procedure that decreases the blood pressure by removing renal nerves. Hypertension is observed as a variable health risk and is frequently associated with mortality and morbidity owing to its alliance with cardiovascular diseases. The progress of catheter supported interventional therapies to disrupt renal sensitive nervous system has revealed impressive results in certifying better blood pressure control in patients having complaints of defiant hypertension. In addition, growing prevalence of uncontrolled as well as defiant drug hypertension is motivating the demand for renal denervation process globally.
Renal denervation is a new move towards the cure of resistant hypertension. It is an endovascular catheter, invasive based procedure that includes the utilization of radiofrequency ablation. Various devices have been officially approved for this procedure. The occurrence of hypertension has been growing worldwide, in spite of the availability of efficient anti-hypertensive medicines. Hypertension stays uncontrolled in the case of quite a few patients for a variety of reasons, involving insufficient treatment. Soaring prevalence of therapy-resistant and uncontrolled hypertension coupled with the small duration &enduring effect of renal denervation and the fast development of RDN devices are reasons that are expected to drive the growth of the renal denervation devices industry.
The global market for RDN equipment is projected to develop with growing incidences of hypertension coupled with the aging population. RDN procedure is accepted to take over the drug treatment technique for uncontrolled hypertension, owing to the reduced treatment time and high level of safety. Escalating market alliance among the market players to bring in better technology will assist in gaining a competitive lead in this budding market. The market for RDN equipment and related processes will also considerably benefit from soaring adoption of RDN process owing to advantages such as radically reduced treatment times and rising safety level of these operations over conventional drug-based therapeutic procedures for uncontrolled hypertension.
Growing collaboration of key players in the industry for bringing in technically superior RDN devices will assist the industry in gaining a competitive edge. Increasing incidence of hypertension amongst urbanized inhabitants has considerably contributed to the expansion of the global renal denervation devices industry. Renal nerves are directly influenced by high blood pressure. The lower consciousness of equipment in contrast to drug-based treatment along with uneven reimbursement regulations will obstruct the expansion of the overall industry over the forecast period.
The market can be segmented into ultrasound based renal denervation, radiofrequency based renal derivation system, micro infusion caterer based renal denervation systems, and renal sympathetic denervation by technology. Radio frequency based radio denervation is expected to capture maximum revenue owing to benefits such as safety and time efficiency. Medtronic symplicity product generated maximum revenue and had achieved more than half of the market in the recent years. It is specially designed to bring radio frequency (RF) energy throughout the wall of the renal blood vessel to attain renal denervation. It comprises of symplicity generator and symplicity catheter. Furthermore, another equipment acquiring popularity is recor’s percutaneous renal denervation system which has two main components. They are a portable, automated customized paradise generator, and a french ultrasound energy deliverance paradise catheter.
By geography, the market can be segregated into North America, Asia Pacific, Europe and Rest of the world. Europe is expected to capture maximum revenue over the forecast period owing growing research and development activities in this field to make these devices more efficient. North America is projected to follow Europe regarding revenue generation, over the forecast period owing to increasing number of FDA approvals in U.S. coupled with increasing occurrence of uncontrolled hypertension due to rapid urbanization. Asia Pacific is expected to grow rapidly over the forecast period owing to increasing aged population combined with rising presence of diabetes.
Expansion in the renal denervation industry will be driven initially by demand for a novel intervention to cure resistant hypertension. This tool has the great potential to transform the cardiac field, offering a modestly invasive solution where nothing at present exists. The renal denervation market is at the initial stage, and the key players are conducting research & development activities to introduce highly differentiated product so that they can have a better grip in revenue generation over the forecast period. The key market players are trying their best to incorporate latest innovations in their products so that they can develop it as their core competence. The renal denervation market is at an initial stage, so it is less fragmented. The key players in the market are Kona Medical, Cardio Sonic, Covidien PLC, Medtronic Inc, Boston Scientific Corporation, and St. Jude Medical.
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.